Memantine
- Generic Name
- Memantine
- Brand Names
- Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK
- Drug Type
- Small Molecule
- Chemical Formula
- C12H21N
- CAS Number
- 19982-08-2
- Unique Ingredient Identifier
- W8O17SJF3T
- Background
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . ...
- Indication
Memantine is used to manage moderate to severe Alzheimer's dementia .
...
- Associated Conditions
- Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia
- Associated Therapies
- -
The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2013-08-14
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 232
- Registration Number
- NCT01921972
Brain Aging and Treatment Response in Geriatric Depression
- Conditions
- Interventions
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 115
- Registration Number
- NCT01902004
- Locations
- 🇺🇸
UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los Angeles, California, United States
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
- Conditions
- Interventions
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 60
- Registration Number
- NCT01876823
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Memantine Monotherapy for Executive Dysfunction and ADHD
- Conditions
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2013-09-24
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT01844427
Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 10
- Registration Number
- NCT01744444
- Locations
- 🇫🇷
Hôpital Neurologique Unité de Neuro-Ophtalmologie, Bron, France
A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 542
- Registration Number
- NCT01677754
- Locations
- 🇺🇸
Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States
🇨🇦Vancouver Island Health Authority, Victoria, British Columbia, Canada
🇺🇸Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
Randomised Controlled Trial of Memantine in Fibromyalgia
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- Aragon Institute of Health Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT01653457
- Locations
- 🇪🇸
Mental Health Unit, Primary Care Center "Torrero"., Zaragoza, Spain
Functional Neuroimaging of Alcoholism Vulnerability (PIT)
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Yale University
- Target Recruit Count
- 71
- Registration Number
- NCT01585168
- Locations
- 🇺🇸
Olin Neuropsychiatry Research Center at the Institute of Living, Hartford Hospital, Hartford, Connecticut, United States
Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 80
- Registration Number
- NCT01555697
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
- Conditions
- Interventions
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 130
- Registration Number
- NCT01535040
- Locations
- 🇺🇸
Wake Forest Cancer Center CCOP Research Base, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.